[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606584":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":19,"responsibleParty":26,"collaborators":19,"id":30,"slug":19,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":19,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":39,"targetDuration":19,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":19,"overallStatus":48,"whyStopped":19,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":19},{"fullName":5,"class":6},"Zhejiang Cancer Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"UCB-MNCs","EXPERIMENTAL","UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation",[13],"Biological: UCB-MNCs",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","UCB-MNCs were administered via intravenous infusion three times, once per week, with a dose of 3×10⁸ cells per infusion.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Ji ZHU","CONTACT","0571-88128212","zhuji@zjcc.org.cn",{"type":27,"investigatorFullName":28,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Ji Zhu","Principal Investigator","100606584",false,"NCT07177456","Study on Safety and Efficacy of UCB-MNCs for Radiation-induced Lung Injury","Study on the Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in the Treatment of Radiation-induced Lung Injury","Inclusion Criteria:\n\n1. Ages 18-75 years,with no restriction on gender;\n2. History of chest radiotherapy;\n3. Diagnosed with grade 2-3 radiation-induced lung injury according to CTCAE 4.0 classification criteria in \"Diagnosis and Treatment of Radiation-induced Lung Injury\";\n4. Inadequate response to conventional treatment for two weeks, with no relief or progressive worsening of symptoms;\n5. Well-controlled tumor for ≥3 months;\n6. No significant liver or kidney dysfunction: ALT, AST ≤ 3 times the upper limit of normal, serum Cr and BUN ≤ 2 times the upper limit of normal;\n7. Expected survival ≥ 3 months;\n8. Informed consent signed voluntarily by the patient;\n9. Willing and able to receive treatment and follow-up as required by the protocol, and able to comply with basic treatment as directed by the physician.\n\nExclusion Criteria:\n\n1. Severe cardiac insufficiency (such as NYHA class III or IV), uncontrolled hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥110mmHg);\n2. Positive for hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or syphilis;\n3. ECOG score ≥2;\n4. Currently participating in or participated in other clinical trials within 4 weeks;\n5. History of allergies or known allergy to the study preparation;\n6. Patients with psychiatric disorders who cannot cooperate with treatment; (7) Pregnant or lactating women.","ALL","18 Years","75 Years",{"count":40,"type":41},10,"ESTIMATED","INTERVENTIONAL",[44],"EARLY_PHASE1","This study aims to evaluate the safety and efficacy of the umbilical cord blood mononuclear cells (UCB-MNCs) therapy for radiation-induced lung injuryr (RILI) by observing factors related to the therapeutic effect and adverse reactions of UCB-MNCs in treating RILI .",[47],"Radiation-induced Lung Injury","NOT_YET_RECRUITING","2025-09-16",{"date":51,"type":52},"2025-09-17","ACTUAL",{"date":54,"type":41},"2025-10-01",{"date":56,"type":41},"2026-12-31",{"name":5,"class":6}]